Gathering the record
Relay is organizing the evidence and source boundaries.
Heterogeneous animal-derived thymic peptide mixture
An animal-derived thymus extract discussed for immune function. It is a mixture, rather than one defined peptide.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Small regional human studies exist, but robust independently replicated controlled evidence is limited.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Published reports are not sufficient to characterize uncommon immune, allergic, contamination, or longer-term risks across heterogeneous products.
Other human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourcePublished reports are not sufficient to characterize uncommon immune, allergic, contamination, or longer-term risks across heterogeneous products.
Other human evidenceLow-frequency estimates are sensitive to sample size, follow-up, ascertainment, formulation, and population.
Open sourceRelay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryMarketed in some countries; not FDA-approved in the United States. Which components are active, whether products are comparable, and whether clinically meaningful immune outcomes reproduce in modern trials.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
An 80-person regional study compared a defined thymic-extract product plus historical standard care with control treatment in severe COVID-19.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 10 days | 10 mg | Daily |
The mixture, disease setting, older concomitant treatments, and limited independent replication constrain interpretation. This is not a validated general immunity or longevity protocol.
Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients Full text · Patients and methodsThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
An 80-patient regional report describes masked random allocation to Thymalin plus historical standard care or control care in severe COVID-19.
Population: Adults hospitalized with severe COVID-19
Design: Regional controlled study reporting masked random allocation by an independent statistician
Mechanisms
Older and regional studies explore immune and aging-related outcomes. Heterogeneous composition, limited modern independent replication, and variable designs constrain broad conclusions.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Regionally concentrated and heterogeneous human literature with mixture-standardization constraints.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Which components are active, whether products are comparable, and whether clinically meaningful immune outcomes reproduce in modern trials.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The small regional study, historical concomitant treatments, and limited independent replication constrain generalization. The animal-derived mixture and limited product characterization constrain transfer to other products, populations, or illnesses. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Regional controlled study reporting masked random allocation by an independent statistician
Adults hospitalized with severe COVID-19
Endpoints were not fully described in the current record.
The regional study reported immune and clinical differences between groups receiving Thymalin-containing treatment or control care.
Study administration: Thymalin 10 mg intramuscularly daily plus historical standard care versus saline plus standard care
Limitations: Small regional study, historical concomitant treatments, heterogeneous extract, and limited independent replication constrain generalization.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
DOI 10.1134/S2079057021040068